Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006371 | A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 27, 2012 | clinicaltrials |
| NCT00005612 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer(ETC) | terminated | Phase 1 / Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER |
| 1 |
| Sep 26, 2012 |
| clinicaltrials |
| NCT00516841 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | 16 | Facet BiotechINDUSTRY | 2 | Aug 23, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00058266 | Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy | terminated | Phase 2 | 36 | Northwestern UniversityOTHER | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00471718 | ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 1 / Phase 2 | 27 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00127387 | Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia | terminated | Phase 2 / Phase 3 | 54 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 26, 2012 | clinicaltrials |
| NCT00881725 | A Study of Pre-operative Metformin in Prostate Cancer(ANIMATE) | terminated | Phase 2 | 24 | University Health Network, TorontoOTHER | 1 | Jun 19, 2012 | clinicaltrials |
| NCT00006262 | Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT00050297 | YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer | terminated | Phase 2 | — | Astellas Pharma IncINDUSTRY | 7 | Jun 7, 2012 | clinicaltrials |
| NCT00073970 | Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy | terminated | Phase 2 | 37 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00231829 | A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers | terminated | Phase 2 | 23 | Mark H. EinsteinOTHER | 1 | Apr 24, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT01340599 | Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery | terminated | Phase 2 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 15, 2012 | clinicaltrials |
| NCT01132404 | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 | terminated | Phase 1 / Phase 2 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 31, 2012 | clinicaltrials |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients(MIMOSA) | terminated | Phase 2 / Phase 3 | 888 | Menarini GroupINDUSTRY | 9 | Nov 24, 2011 | clinicaltrials |
| NCT00926107 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse | terminated | Phase 2 | 9 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 10, 2011 | clinicaltrials |
| NCT00452387 | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 22 | Accelerated Community Oncology Research NetworkOTHER | 1 | Sep 16, 2011 | clinicaltrials |
| NCT00117312 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | terminated | Phase 2 | 37 | Ferring PharmaceuticalsINDUSTRY | 1 | May 23, 2011 | clinicaltrials |
| NCT00215657 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | terminated | Phase 2 | 131 | Ferring PharmaceuticalsINDUSTRY | 0 | May 20, 2011 | clinicaltrials |
| NCT00245466 | Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients | terminated | Phase 2 | 88 | Ferring PharmaceuticalsINDUSTRY | 0 | May 20, 2011 | clinicaltrials |
| NCT00577356 | Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer | terminated | Phase 2 | 6 | Benaroya Research InstituteOTHER | 1 | Jan 20, 2011 | clinicaltrials |
| NCT00312442 | Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy | terminated | Phase 2 / Phase 3 | 16 | STEBA FranceINDUSTRY | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00258765 | Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy. | terminated | Phase 2 | 1 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00082212 | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | terminated | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 9, 2010 | clinicaltrials |
| NCT00277290 | Study of XL999 in Patients With Previously Treated Ovarian Cancer | terminated | Phase 2 | 24 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00176527 | Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 40 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00494338 | Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer | terminated | Phase 2 | 6 | SanofiINDUSTRY | 1 | Oct 1, 2009 | clinicaltrials |
| NCT00104130 | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer | terminated | Phase 2 | 53 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 17, 2008 | clinicaltrials |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | terminated | Phase 2 | 40 | Unither PharmaceuticalsINDUSTRY | 0 | Dec 18, 2007 | clinicaltrials |
| NCT00189579 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | terminated | Phase 2 | 45 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00106262 | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | terminated | Phase 2 | 38 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Apr 18, 2007 | clinicaltrials |
| NCT00132756 | Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Morton Plant Mease Health CareOTHER | 1 | Nov 8, 2006 | clinicaltrials |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | terminated | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Sep 15, 2006 | clinicaltrials |
| NCT00194935 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | terminated | Phase 2 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00220532 | Folate and Protection Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 180 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 69 | Cell GenesysINDUSTRY | 1 | Feb 2, 2006 | clinicaltrials |
| NCT00179738 | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. | terminated | Phase 2 | 40 | Celgene CorporationINDUSTRY | 1 | Nov 23, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Sep 27, 2012source: clinicaltrials